DDrare: Database of Drug Development for Rare Diseases

331. 特発性多中心性キャッスルマン病
［臨床試験数：30，薬物数：44（DrugBank：23），標的遺伝子数：30，標的パスウェイ数：148］

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Best Supportive Care (BSC); Bevacizumab; Bortezomib; CNTO 328; CNTO328; CX-4945 oral formulation; Cetuximab; Chimeric murine human anti-IL-6 monoclonal antibody; Cyclophosphamide; Dexamethason; Doxorubicin; Doxorubicin Hydrochloride; Etoposide; Filgrastim; Filgrastim (G-CSF); G-CSF; Hyaluronidase; Interferon-alpha; Liposomal Doxorubicin; Methotrexate; Nelfinavir; Other: Laboratory Biomarker Analysis; Other: Observation Only; Other: Pharmacological Study; Pomalidomide; Prednisone; Rituximab; Rituximab or Rituximab Hyaluronidase Human; RoActemra; SILTUXIMAB; Siltuximab; Sirolimus; Suramin; Temsirolimus; Thalidomide; Thalidomide, cyclophosphamide and prednisone; Tocilizumab; Tocilizumab [RoActemra/Actemra]; Valganciclovir; Valganciclovir (VGC); Valproic Acid; Valproic acid; Vincristine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071190029	25/05/2020	09/10/2019	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)	idiopathic multicentric Castleman's disease Castleman's disease	Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily	Kawakami Atsushi	NULL	Recruiting	>= 18age old	Not applicable	Both	20	Phase 2	Japan
2	NCT01441063 (ClinicalTrials.gov)	September 13, 2011	24/9/2011	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease	Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia	Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
3	NCT01183598 (ClinicalTrials.gov)	August 2006	13/8/2010	A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment	Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment	Castleman's Disease	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	3	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCT2071190029

25/05/2020

09/10/2019

Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)

idiopathic multicentric Castleman's disease
Castleman's disease

Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily

Kawakami Atsushi

NULL

Recruiting

>= 18age old

Not applicable

Both

Phase 2

Japan

NCT01441063
(ClinicalTrials.gov)

September 13, 2011

24/9/2011

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease

Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia

Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)

National Cancer Institute (NCI)

NULL

Completed

18 Years

N/A

All

Phase 2

United States

NCT01183598
(ClinicalTrials.gov)

August 2006

13/8/2010

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment

Castleman's Disease

Drug: tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche

NULL

Completed

18 Years

N/A

Both

Phase 1

United States